Skip to main content
    A

    Akebia Ther (AKBA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.45
    -0.03 (-5.40%)

    Market Cap: $131.67M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    40%(16/40)
    Avg Surprise
    -12.29%

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.04
    Range-$0.07 - -$0.01
    8 analysts
    Revenue Consensus
    $32.80M
    Range$26.26M - $37.80M
    8 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.09
    Range-$0.09 - -$0.09
    1 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.06-50.0%
    60d ago-$0.10+5.3%
    30d ago-$0.10+5.3%
    7d ago-$0.10+5.3%
    Current-$0.09
    Revenue Consensus
    $25.07M
    Range$18.60M - $30.50M
    4 analysts

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCF8.96xFCF Yield11.16%
    Profitability
    Profit Margin-22.60%Operating Margin-10.20%
    ROE-143.80%ROIC-38.86%
    Financial Health
    Debt/Equity2.47xInterest CoverageN/A
    Current Ratio1.36xQuick Ratio1.24x
    Trading Statistics
    Beta0.23Avg Volume8.70M
    52-Week High$1.7552-Week Low$0.36

    Technical Indicators Dashboard

    As of Nov 16, 2026, the price is 41.0% below its 50-day moving average, and the 50-day average is below the 200-day average. The 14-day RSI is 35.0, in the neutral range between 30 and 70.

    Moving Averages

    SMA 10$0.53
    SMA 20$0.59
    SMA 50$0.76
    SMA 200$1.10
    EMA 10$0.53
    EMA 20$0.59
    EMA 50$0.73
    EMA 200$1.15

    MACD

    Line: -0.08Signal: -0.07Hist: -0.01

    ADX

    ADX: 26.7+DI: 19.8-DI: 37.2

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down76.0
    PSAR$0.70

    Bollinger Bands

    Upper Band$0.81
    Lower Band$0.37
    %B Position7424%(Upper)
    Band Width0.17

    RSI (14-Day)

    Neutral
    35.0

    Momentum Oscillators

    Stoch %K25.6
    Stoch %D33.7
    Williams %R-80.1
    ROC (10d)-36.7%
    Momentum-0.26
    CCI (20d)-101.9
    MFI (14d)45.5

    Volatility Measures

    ATR (14d)$0.07(16.3%)
    StdDev (20d)0.11
    Hist Vol214.5%(High)

    Volume Flow

    VWAP$0.46
    OBV-59.4M
    AD Line-116.8M
    CMF (20d)-0.194

    Volume Metrics

    Avg Vol (20d)8.7M
    Vol Ratio0.4x(Low)
    VWMA (20d)$0.58

    Pivot Points

    R3$0.53
    R2$0.51
    R1$0.49
    Pivot Point$0.47
    S1$0.45
    S2$0.43
    S3$0.41

    Advanced Oscillators

    TSI-25.87
    Ultimate Osc52.3
    KST-285.99

    Financial Performance

    Related GNG Research

    No research available

    Be the first to write about AKBA

    News

    AKBA Valuation

    Akebia Ther (AKBA) trades at 24.6x forward earnings.

    Forward P/E
    24.6x
    P/FCF
    9.0x
    P/B
    6.1x
    AKBA valuation multiples

    AKBA Profitability: Margins, ROIC and FCF

    Akebia Ther (AKBA) has a gross margin of 78.9%, an operating margin of -10.2% and a net margin of -22.6%. It posts -38.9% ROIC and a 7.0% FCF margin.

    Gross margin
    78.9%
    Operating margin
    -10.2%
    Net margin
    -22.6%
    ROIC
    -38.9%
    ROE
    -143.8%
    FCF margin
    7.0%
    FCF yield
    11.2%
    AKBA financial statements

    Akebia Ther Competitors

    The companies most similar to Akebia Ther (AKBA) include Anika Therapeutics, Cardiol Therapeutics Inc Class A and Journey Medical.

    Sector: Healthcare

    Companies most similar to Akebia Ther

    AKBA Analyst Ratings

    Akebia Ther (AKBA) has a Buy consensus from 6 analysts: 5 Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell.

    Consensus
    Buy
    Analysts
    6
    Strong Buy
    1
    Buy
    4
    Hold
    1
    Sell
    0
    Strong Sell
    0
    AKBA stock forecast

    AKBA Bull Case vs Bear Case

    Bull case

    • 83.3% of AKBA's analyst ratings are Buy or Strong Buy.

    Bear case

    • AKBA has a -22.6% net profit margin.
    • AKBA's quarterly revenue changed -37.2% year over year.
    • AKBA has a debt-to-equity ratio of 2.5x.

    AKBA Earnings: Beat Rate and Next Report

    Akebia Ther (AKBA) beat the EPS estimate in 4 of the last 8 quarters (50.0%). Its next report is expected on Feb 24, 2027.

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    42.3%
    EPS estimate (fiscal period ending Dec 31, 2026)
    -$0.04
    AKBA earnings history

    AKBA Earnings Date

    AKBA reports Feb 24, 2027. The date is estimated.

    AKBA Earnings Call

    The latest AKBA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    See insider activity

    Updated Nov 5, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology

    Frequently Asked Questions About AKBA

    When does AKBA report earnings?

    Akebia Ther (AKBA) is expected to report earnings on Feb 24, 2027.

    Does AKBA pay dividends?

    Akebia Ther (AKBA) does not currently pay a regular dividend.

    What is AKBA's market cap?

    Akebia Ther (AKBA) has a market capitalization of $131.67M with a current stock price of $0.45.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.